Zevorcabtagene autoleucel (zevor-cel; CT053) is an autologous fully human BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma. Company disclosures report NMPA approval in China and active commercialization in mainland China with ongoing post-marketing data generation.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
CAR T-cell therapy market advances with AI-driven manufacturing improvements and over 250 companies developing 500+ drug candidates, including breakthrough solid tumor treatments and GPC3-targeted therapies for hepatocellular carcinoma.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06825845 |
Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy |
NOT_YET_RECRUITING | |
| NCT06659770 |
A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma |
NOT_YET_RECRUITING |
